Form 13-F position report

GSK PLC

Reported by KEATING INVESTMENT COUNSELORS INC

GSK CUSIP 37733W204 Manager CIK 0001020580

Reported 166,303 shares, down 515 (0.3%) from the prior quarter.

Reported value -8.4%; share count -0.3% vs. the prior quarter.

Reduced
% of reported 13F value 2.1% This manager · Q3 2026
Shares 166,303 Quarter-end amount reported
Reported value $8,010,816 Fair value at quarter end
Consecutive quarters held 8 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 7798000
2022-03-31 7703000
2022-06-30 0
2022-06-30 7659000
2022-09-30 4155000
2022-12-31 6954839
2023-03-31 0
2024-12-31 5533121
2025-03-31 7314344
2025-06-30 7173158
2025-09-30 7748558
2025-12-31 8832545
2026-03-31 9667522
2026-06-30 8744600
2026-09-30 8010816

Quarterly position history

How this manager's reported quarter-end position changed over time.

15 quarters
Quarterly reported position history for GSK PLC held by KEATING INVESTMENT COUNSELORS INC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 166,303 -515 (-0.3%) 2.1% $8,010,816 2026-10-14
Q2 2026 Reduced 166,818 -8,350 (-4.8%) 2.4% $8,744,600 2026-07-16
Q1 2026 Reduced 175,168 -4,941 (-2.7%) 2.39% $9,667,522 2026-04-27
Q4 2025 Added 180,109 +578 (0.3%) 2.45% $8,832,545 2026-01-30
Q3 2025 Reduced 179,531 -7,270 (-3.9%) 2.21% $7,748,558 2025-10-27
Q2 2025 Reduced 186,801 -2,005 (-1.1%) 2.17% $7,173,158 2025-08-07
Q1 2025 Added 188,806 +25,201 (15.4%) 2.21% $7,314,344 2025-05-12
Q4 2024 New 163,605 +163,605 (0.0%) 1.73% $5,533,121 2025-01-31
Q1 2023 Reduced 0 -197,918 (-100.0%) 0 $0 2023-05-04
Q4 2022 Added 197,918 +56,742 (40.2%) 2.72% $6,954,839 2023-02-08
Q3 2022 Reduced 141,176 -34,769 (-19.8%) 1.86% $4,155,000 2022-11-03
Q2 2022 New 175,945 +175,945 (0.0%) 3.23% $7,659,000 2022-08-03
Q2 2022 Reduced 0 -176,828 (-100.0%) 0 $0 2022-08-03
Q1 2022 Unchanged 176,828 0 (0.0%) 3.3% $7,703,000 2022-04-28
Q4 2021 Added 176,828 +133 (0.1%) 3.45% $7,798,000 2022-01-26
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

1101 managers reported GSK PLC for Q3 2026.

Managers reporting GSK PLC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
FMR LLC Reduced 64,920,926 -40,715 0.13% $3,127,240,971 17 qtrs
Dodge & Cox Reduced 43,183,117 -5,014,397 1.12% $2,080,130,746 17 qtrs
Fisher Asset Management LLC Reduced 35,351,693 -371,099 0.49% $1,702,891,094 17 qtrs
PRIMECAP MANAGEMENT CO CA Added 25,192,138 +10,070 0.75% $1,213,505,291 17 qtrs
WELLINGTON MANAGEMENT GROUP LLP Reduced 9,650,852 -1,745,397 0.08% $464,881,541 17 qtrs
JTC Employer Solutions Trustee Ltd Reduced 8,077,477 -515,510 33.51% $389,173,000 17 qtrs
ROYAL BANK OF CANADA Added 7,652,143 +63,215 0.06% $368,604,000 17 qtrs
MORGAN STANLEY Reduced 7,584,742 -72,820 0.02% $365,357,075 17 qtrs
PRICE T ROWE ASSOCIATES INC MD Reduced 6,712,097 -211,545 0.03% $323,323,000 17 qtrs
The Goldman Sachs Group Inc Reduced 6,021,779 -349,663 0.02% $290,069,075 17 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
October 14, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
151,202
Shared
0
None
15,101

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.